Tenax Therapeutics Inc., of Morrisville, N.C., said the FDA requested an additional clinical trial for levosimendan after a pre-NDA meeting that reviewed the potential to submit a marketing application for the drug to treat patients undergoing coronary artery bypass grafting to reduce the risk of low cardiac output syndrome and for the treatment of patients with acute decompensated heart failure.